Answers are grounded in this paper and cite their sources.
Topical 0.1% tacrolimus was used for treatment of localized lesions associated with 10 cases of discoid lupus erythematosus (DLE) and two cases of pemphigus erythematosus (PE) either as a sole therapy (n=2) or as an adjunctive treatment (n=10). Eight of 10 dogs with DLE and both dogs with PE were improved following 8 weeks of topical application. In six of the eight dogs that improved, other medications were discontinued. No adverse effects in clinical or laboratory parameters were noted throughout the study.
No takes yet. Share an insight, caveat, or question.
Griffies et al. (2004) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: